Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun 17;98(12):1993-8.
doi: 10.1038/sj.bjc.6604400. Epub 2008 Jun 10.

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

D Loussouarn  1 , L Campion, C Sagan, J-S Frenel, F Dravet, J-M Classe, R Pioud-Martigny, D Berton-Rigaud, E Bourbouloux, J-F Mosnier, F-R Bataille, M Campone
Affiliations

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

D Loussouarn et al. Br J Cancer. .

Abstract

Carcinoma cells lack syndecan-1 expression when they are transiting from an epithelial to a less-differentiated mesenchymal phenotype (epithelial-mesenchymal transition, EMT). Furthermore, a shift of syndecan-1 expression from malignant epithelial cells to reactive stromal cells has also been observed during progression of many carcinomas. Finally, epithelial and/or stromal syndecan-1 expression is of prognostic value in many carcinomas. Because recent results are contradictory in breast carcinomas, we have re-evaluated the prognostic significance of syndecan-1 expression in a cohort of 80 patients with invasive ductal breast carcinomas. The tumours from 80 patients diagnosed with invasive ductal breast carcinomas were used to construct a tissue microarray, which was stained with syndecan-1 by immunohistochemistry. We correlated syndecan-1 expression with clinicopathologic parameters and relapse-free survival (RFS). Exclusive epithelial expression of syndecan-1 is observed in 61.25% of the patients, whereas exclusive stromal expression is observed in 30% of the patients. Only 8.75% of the patients had both stromal and epithelial expressions of syndecan-1. A significant correlation was found between the loss of syndecan-1 epithelial expression and the syndecan-1 stromal expression with high grade of malignancy (P=0.011). The loss of syndecan-1 epithelial expression is correlated with RFS (P=0.001). Using multivariate Cox analysis, loss of epithelial syndecan-1 expression was the only prognostic indicator (P<0.001). We concluded that the loss of syndecan-1 epithelial expression was of strong prognostic value in breast carcinomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Intense membranous immunostaining of carcinoma cells; no stromal immunostaining (E+/S−). (B) Immunostaining of both carcinoma cells and stroma (E+S+). (C) Stromal immunostaining and no epithelial immunostaining (E−S+).
Figure 2
Figure 2
Kaplan–Meier RFS curves according to epithelial status. (A) Separate epithelium/stroma status. (B) Epithelium positive vs epithelium negative status.
Figure 3
Figure 3
Estimate distribution of absence of epithelial expression (10 000 bootstraped data sets).
See this image and copyright information in PMC

References

    1. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79: 4558–4564 - PMC - PubMed
    1. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Mauri FA, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98: 474–483 - PubMed
    1. Conejo JR, Kleef J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Büchler MW (2000) Syndecan-1 is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88: 12–20 - PubMed
    1. Elston CW, Ellis IQ (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410 - PubMed
    1. Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92: 1074–1081 - PMC - PubMed